References
- Chiva-Blanch G, Badimon L. 2019. Benefits and risks of moderate alcohol consumption on cardiovascular disease: current findings and controversies. Nutrients. 12(1):108.
- Friedman FK, West D, Dewick PM, Gelboin HV. 1985. Specificity of medicarpin and related isoflavonoids in inhibition of rat hepatic mixed function oxidase activity. Pharmacology. 31(5):289–293.
- Gou SH, Liu J, He M, Qiang Y, Ni JM. 2016. Quantification and bio-assay of α-glucosidase inhibitors from the roots of Glycyrrhiza uralensis Fisch . Nat Prod Res. 30(18):2130–2134.
- Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, Wickremasinghe AR, de Silva HJ. 2013. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol. 28(1):142–147.
- Li XJ, Sun R, and Liu RP. 2019. Natural products in licorice for the therapy of liver diseases: Progress and future opportunities. Pharmacol Res. 144: 210–226.
- Liou CJ, Lee YK, Ting NC, Chen YL, Shen SC, Wu SJ, Huang WC. 2019. Protective effects of licochalcone A ameliorates obesity and non-alcoholic fatty liver disease via promotion of the Sirt-1/AMPK pathway in mice fed a high-fat diet. Cells. 8(5):447.
- Liu J, Wang YQ, Gou SH, Ni JM. 2014. A study of the pseudo-aldosteronism toxicity of licorice flavonoid dispersible tablets. Asian J Tradit Med. 9(4):88–97.
- Liu ZJ, Zhong J, Zhang M, Chen ZH, Wang JY, Chen HY, Wang XQ, Zhang B. 2019. The alexipharmic mechanisms of five licorice ingredients involved in CYP450 and Nrf2 pathways in Paraquat-induced mice acute lung injury. Oxid Med Cell Longev. 2019:7283104.
- Miele L, Targher G. 2015. Understanding the association between developing a fatty liver and subsequent cardio-metabolic complications. Expert Rev Gastroenterol Hepatol. 9(10):1243–1245.
- Mishra A, Younossi ZM. 2012. Epidemiology and natural history of non-alcoholic fatty liver disease. J Clin Exp Hepatol. 2(2):135–144.
- Mostafa ME, Shaaban AA, Salem HA. 2019. Dimethylfumarate ameliorates hepatic injury and fibrosis induced by carbon tetrachloride. Chem Biol Interact. 302:53–60.
- Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagstrom H, Yoon SK, Charatcharoenwitthaya P, et al. 2014. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 11(7):e1001680.
- Xu YR, Ni JM, Meng QG, Gao Y, Fan B. 2005. Preliminary study on the alpha-glucosidase inhibitor from Glycyrrhiza uralensis Fisch. Zhong Yao Cai. 28(10):890–891.
- Yan MZ, Ye LH, Yin ST, Lu X, Liu XT, Lu SY, Cui JL, Fan LH, Kaplowitz N, Hu HB. 2018. Glycycoumarin protects mice against acetaminophen-induced liver injury predominantly via activating sustained autophagy. Br J Pharmacol. 175(19):3747–3757.
- Yang R, Wang LQ, Yuan BC, Liu Y. 2015. The pharmacological activities of licorice. Planta Med. 81(18):1654–1669.